首页> 外文期刊>Journal of pharmaceutical sciences. >Ocular Delivery of Flurbiprofen Based on Eudragit (R) E-Flurbiprofen Complex Dispersed in Aqueous Solution: Preparation, Characterization, In Vitro Corneal Penetration, and Ocular Irritation
【24h】

Ocular Delivery of Flurbiprofen Based on Eudragit (R) E-Flurbiprofen Complex Dispersed in Aqueous Solution: Preparation, Characterization, In Vitro Corneal Penetration, and Ocular Irritation

机译:基于分散在水溶液中的Eudragit(R)E-氟比洛芬复合物的氟比洛芬的眼部递送:制备,表征,体外角膜穿透和眼刺激性

获取原文
获取原文并翻译 | 示例
           

摘要

A novel ophthalmic formulation based on the ionic complexation between Eudragit E 100 (EU) and flurbiprofen (FB) is proposed. The selected complex composition, named EU-FBH50Cl50, had the basic groups of EU completely neutralized with equal molar amounts of FB and HCl. This complex, obtained in the solid state, exhibited a high aqueous compatibility producing a colloidal dispersion with a high positive electrokinetic potential, in which more than 99% of FB was ionically condensed with EU. In bicompartimental Franz cells, FB diffusion from the complex was very slow. However, dispersion in 0.9% NaCl increased the FB release through an ionic exchange, providing an optimal constant rate of delivery. Corneal FB permeation from 0.1% EU-FBH50-Cl-50 dispersed in 0.9% NaCl solution was substantially more effective compared with 0.1% FB solution, EU-FBH50-Cl-50(Dex), or Tolerane((R)) (a marketed formulation). This complex formulation was shown to be innocuous for rabbit ocular tissues because no irritant effects were evidenced. (c) 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:3859-3868, 2014
机译:提出了一种基于Eudragit E 100(EU)和氟比洛芬(FB)之间离子络合的新型眼科制剂。选择的复杂组合物名为EU-FBH50Cl50,具有相同摩尔量的FB和HCl完全中和了EU的碱性基团。以固态获得的该配合物表现出高的水相容性,从而产生具有高的正电动势的胶体分散体,其中超过99%的FB与EU离子化缩合。在双室Franz细胞中,FB从复合物中的扩散非常缓慢。但是,分散在0.9%NaCl中会通过离子交换增加FB释放,从而提供最佳的恒定输送速率。与0.1%FB溶液,EU-FBH50-Cl-50(Dex)或Tolerane(R)相比,分散在0.9%NaCl溶液中的0.1%EU-FBH50-Cl-50的角膜FB渗透明显更有效。市售配方)。该复合制剂对兔眼组织无害,因为没有刺激性证据。 (c)2014年Wiley Periodicals,Inc.和美国药剂师协会J Pharm Sci 103:3859-3868,2014年

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号